OTC: AAVXF - ABIVAX Société Anonyme

六个月盈利: -51.35%
部门: Healthcare

促销时间表 ABIVAX Société Anonyme

先进的时间表 简单图表
Financial Markets by TradingView

关于公司

ABIVAX Société Anonyme, a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. The company is also developing obefazimod in Phase IIb/III pivotal planned studies for the treatment of Crohn's Disease; and completed Phase IIa clinical trials for the treatment of rheumatoid arthritis diseases.

更多详情
In addition, the company develops ABX 196, an immune enhancer candidate that is in Phase 1/2 POC clinical trial for the treatment of hepatocellular cancer, as well as a pre-clinical drug for the treatment of respiratory syncytial virus. It has license agreement with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета eur
Сайт https://www.abivax.com
Цена ао 11.05
每日价格变化: 0% (7.37)
每周价格变化: -33.3% (11.05)
每月价格变化: -33.3% (11.05)
3个月内价格变化: -33.3% (11.05)
六个月内的价格变化: -51.35% (15.15)
每年价格变化: -27.67% (10.19)
3年内价格变化: -76.97% (32)
5年内价格变化: -26.15% (9.98)
10年价格变化: 0% (7.37)
年初以来价格变化: -33.3% (11.05)
所有参数

低估

姓名 意义 年级
P/S 86.25 1
P/BV 2.03 7
P/E 0 0
EV/EBITDA -1.54 0
全部的: 4

效率

姓名 意义 年级
ROA, % -45.17 0
ROE, % -75.37 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.4212 10
全部的: 9.6

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 19991.3 10
盈利能力 Ebitda, % 300.08 10
盈利能力 EPS, % 15.22 3
全部的: 8.6
更多详情

机构 体积 分享, %
iShares MSCI EAFE Small Cap ETF 72366 0.12
abrdn World Healthcare Fund 37000 0.06
College Retirement Equities Fund-Stock Account 26827 0.04
Fidelity SAI International Small Cap Index Fund 9418 0.01
SSgA SPDR ETFS Europe I-SPDR MSCI Europe Small Cap UCITS ETF 7659 0.01
State Street Inst Inv Tr-State St All Cap Glb Equity ex-US Index Port 3874 0.01
iShares MSCI Europe Small Cap ETF 3094 0
SSgA SPDR ETFS Europe I-SPDR MSCI Europe Small Cap Value Weighted 2172 0
SPDR (R) Portfolio Europe ETF 520 0
DBX ETF Trust-X-trackers MSCI Eurozone Hedged Equity 194 0



导师 职称 支付 出生年份
Dr. Philippe Pouletty M.D., Ph.D. Founder & Director N/A 1958 (67 年)
Mr. Marc M. P. de Garidel M.B.A. CEO & Director 850.26k 1958 (67 年)
Mr. Didier Blondel EVP, CFO & Board Secretary N/A 1964 (61 年)
Mr. Didier Scherrer Ph.D. Chief Scientific Officer N/A 1970 (55 年)
Mr. Patrick Malloy Senior Vice President of Investor Relations N/A
Ms. Ida Hatoum Chief People & Compliance Officer N/A 1975 (50 年)
Mr. Pierre Courteille M.B.A. Chief Business Officer N/A 1969 (56 年)
Mr. Michael Ferguson B.S., M.B.A. Chief Commercial Officer N/A 1978 (47 年)
Mr. Jerome Denis Ph.D. Executive Vice President of Process Development & Manufacturing N/A
Ms. Ana Sharma M.P.H. VP & Global Head of Quality

地址: France, Paris, 7-11 boulevard Haussmann - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.abivax.com